Researchers hailing from Araraquara School of Pharmaceutical Sciences in Brazil have unveiled compelling outcomes from trials of a novel agent designed to combat tuberculosis. Their research, documented in ACS Omega, indicates that an iron-based compound, encapsulated within lipid nanoparticles, managed to completely eradicate the tuberculosis bacillus in the lungs of mice in just 30 days.
Tuberculosis is widely recognized as the most perilous bacterial infection globally. According to the World Health Organization (WHO), this ailment results in death for 50% of untreated individuals; however, approximately 85% of patients recover when adhering strictly to medical advice.
Conventional treatment necessitates the daily ingestion of at least four different antibiotics for a duration spanning six months, and if resistance is present, therapy can extend up to two years. This protracted regimen presents challenges for adherence, particularly for vulnerable populations such as the homeless or those struggling with alcohol dependency.
The scientific team evaluated ferroin—a complex organic compound comprising iron sulfate and ortho-phenanthroline. To ensure protection and regulated release, this substance was incorporated into lipid nanoparticles. Laboratory assessments revealed that the agent significantly potentiated the effects of both rifampicin and prothionamide by compromising the bacterial cell wall, similar to the mechanism employed by penicillins.
A concern voiced by the researchers is that a subset of patients discontinues antibiotic intake mid-course, thereby fostering drug resistance within the bacterial population, which immediately curtails treatment avenues.
In rodent trials, the experimental drug demonstrated superior efficacy compared to isoniazid, a standard antibiotic utilized within Brazil’s healthcare system. While further clinical trials are undoubtedly necessary, the developers are confident in the development’s substantial promise. Should its safety and effectiveness be validated, treatment could become both more accessible and shorter in duration, critically reducing the chances of drug resistance evolving.
About the Author
